The Impact of the COVID-19 Pandemic on Follow-Up and Management of Cancer Patients
Received Date : 20 Apr 2021
Accepted Date : 05 Sep 2021
Available Online : 17 Sep 2021
Doi: 10.37047/jos.2021-83957 - Article's Language: EN
J Oncol Sci. 2021;7(3):98-105
This is an open access article under the CC BY-NC-ND license
Objective: This study aimed to evaluate the impact of the coronavirus disease-2019 (COVID-19) pandemic on the follow-up and management of cancer patients. Material and Methods: A survey consisting of 15 questions asking whether there was a delay in followup or treatment of cancer during the COVID-19 pandemic was applied to the cancer patients who were admitted to our medical oncology outpatient clinic for follow-up or treatment. Results: A total of 209 cancer patients were included in this study. In 56 (26.8%) patients, there was a delay in the follow-up or treatment of cancer. The delay in cancer treatment occurred in 37 (66%) patients, and the delay in the follow-up of cancer occurred in 19 (34%) patients. The median delay in the follow-up and treatment of cancer was both 30 days (range 1-120) and (range 2-120), respectively. 12.5% of all patients who encountered delays in cancer follow-up or treatment had subsequent cancer-related complications. Also, the delay was significantly higher in quarantined patients and patients diagnosed with severe acute respiratory syndromecoronavirus- 2. In binary logistic regression analysis, living in rural areas and being quarantined due to the COVID-19 pandemic were determined as independent predictors of the delay. Conclusion: The COVID-19 outbreak caused delays in the follow-up and treatment of cancer patients, and acute complications arose due to unavoidable disruptions. To prevent long-term negative consequences of delays in cancer follow- up and treatment, it is necessary to adapt the treatments judiciously without sacrificing patient safety and care.
  1. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. [Crossref]  [PubMed]  [PMC] 
  2. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5): 343-360. [Crossref]  [PubMed]  [PMC] 
  3. Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020;127:104371. [Crossref]  [PubMed]  [PMC] 
  4. Demirbilek Y, Pehlivantürk G, Özgüler ZÖ, Alp Meşe E. COVID-19 outbreak control, example of ministry of health of Turkey. Turk J Med Sci. 2020;50(SI-1):489-494. [Crossref]  [PubMed]  [PMC] 
  5. Ministry of Health [Internet]. ©2021 Ministry of Health. COVID-19 Information Platform. 7 December 2020. Available from: [Link] 
  6. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034. Erratum in: Lancet Oncol. 2021;22(1):e5. [Crossref]  [PubMed]  [PMC] 
  7. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416-1424. [Crossref]  [PubMed] 
  8. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3): 335-337. [Crossref]  [PubMed]  [PMC] 
  9. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21(7):893-903. [Crossref]  [PubMed]  [PMC] 
  10. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8): 1218-1223. [Crossref]  [PubMed]  [PMC] 
  11. Lee LY, Cazier JB, Angelis V, et al; UK Coronavirus Monitoring Project Team, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-1926. Erratum in: Lancet. 2020;396(10250):534. [Crossref]  [PubMed]  [PMC] 
  12. Barlesi F, Foulon S, Bayle A, et al. Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Cancer Research. AACR Annual Meeting. 2020; 80(16). [Crossref] 
  13. Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452-455. [Crossref]  [PubMed]  [PMC] 
  14. Passaro A, Addeo A, Von Garnier C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open. 2020;5(Suppl 3):e00 0820. [Crossref]  [PubMed]  [PMC] 
  15. Colombo I, Zaccarelli E, Del Grande M, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. ESMO Open. 2020;5(Suppl 3):e000827. [Crossref]  [PubMed]  [PMC] 
  16. Tachibana I, Ferguson EL, Mahenthiran A, et al. Delaying cancer cases in urology during COVID-19: review of the literature. J Urol. 2020;204(5):926-933. [Crossref]  [PubMed] 
  17. Maio M, Hamid O, Larkin J, et al. Immune checkpoint inhibitors for cancer therapy in the COVID-19 Era. Clin Cancer Res. 2020;26(16): 4201-4205. [Crossref]  [PubMed] 
  18. Guven DC, Aktas BY, Aksun MS, et al. COVID-19 pandemic: changes in cancer admissions. BMJ Support Palliat Care. 2020 Jul 14:bmjspcare-2020-002468. [Crossref]  [PubMed] 
  19. Akagunduz B, Ozer M, Karacin C, Atcı MM, Yıldırım HC, Unver E. Impact of coronaphobia on treatment and follow-up compliance of cancer patients. Future Oncol. 2021;17(20):2621-2629. [Crossref]  [PubMed] 
  20. Erdem D, Karaman I. Awareness and perceptions related to COVID-19 among cancer patients: A survey in oncology department. Eur J Cancer Care (Engl). 2020;29(6):e13309. [Crossref]  [PubMed]  [PMC] 
  21. Sud A, Jones ME, Broggio J, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020;31(8):1065-1074. [Crossref]  [PubMed]  [PMC] 
  22. Sud A, Torr B, Jones ME, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21(8):1035-1044. [Crossref]  [PubMed]  [PMC] 
  23. Alimoglu O, Erol CI, Kilic F, Baysal H. Cancer surgery during the Covid-19 pandemic in Turkey. Int J Surg. 2020;79:54-55. [Crossref]  [PubMed]  [PMC] 
  24. Finley C, Prashad A, Camuso N, et al. Guidance for management of cancer surgery during the COVID-19 pandemic. Can J Surg. 2020;63(22):S2-S4. [Crossref]  [PubMed]  [PMC] 
  25. Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open. 2020;5(Suppl 3):e000826. [Crossref]  [PubMed]  [PMC] 
  26. Bernhardt D, Wick W, Weiss SE, et al. Neuro-oncology management during the COVID-19 pandemic with a focus on WHO Grade III and IV Gliomas. Neuro Oncol. 2020;22(7):928-35. [Crossref]  [PubMed]  [PMC]